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Simonetta VannucchiaGlycosaminoglycans in normal human plasma, mainly
represented by chondroitin sulfates and heparan sulfates/
heparin (HSGAGs), show a specific distribution in the
Cohn–Oncley fractions of human plasma. In the present
study we investigated their effects on coagulation. Plasma
was fractionated following the procedure of Cohn–Oncley,
and each fraction was treated for extraction of
glycosaminoglycans after extensive proteolysis; the
anticoagulant activity in the extracted samples was
measured by activated partial thromboplastin time (APTT).
The effects of the samples containing HSGAGs on factor II
and factor X activities, before and after treatment with
heparinase I, were also measured. The molecular weight of
HSGAGs was determined by polyacrylamide gel-
electrophoresis. Cryoprecipitate and fraction I, fraction
IIRIII, and fraction IV-1 (the fractions containing HSGAGs)
prolonged the APTT, whereas fractions IV-4 and V had no
effect on the APTT. Fractions containing HSGAGs showed
effects on factor II and factor X activities that were sensitive
to heparinase I treatment. Themolecular weight of HSGAGs
recovered in cryoprecipitate and fraction I was 15–18kDa;
that of HSGAGs recovered in fraction IV-1 was 12.0 kDa. Inopyright © Lippincott Williams & Wilkins. Unauth
0957-5235  2008 Wolters Kluwer Health | Lippincott Williams & Wilkinsconclusion, these results demonstrate that HSGAGs of
different molecular weight, endowed with anticoagulant
activity, circulate in normal human plasma in association
with specific proteins involved in the regulation of
hemostasis; and that endogenous HSGAGs play a role in
maintaining the antithrombotic/hemostatic balance in
normal human plasma. Blood Coagul Fibrinolysis 19:349–
354  2008 Wolters Kluwer Health | Lippincott Williams &
Wilkins.
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Human tissues, including plasma, contain glycosamino-
glycans, which are polymers of disaccharide units. Glyco-
saminoglycans found in human tissues differ in molecular
structure and the degree of sulfation. Hyaluronic acid is
composed of acetyl glucosamine and glucuronic acid, and
it is not sulfated. Keratan sulfate is sulfated, and it is
composed of acetyl glucosamine and galactose. The class
of chondroitin sulfate glycosaminoglycans (CSGAGs)
encompasses chondroitin sulfate A and chondroitin sul-
fate C, which are composed of acetyl galactosamine and
glucuronic acid. Chondroitin sulfate A and chondroitin
sulfate C show various degrees of sulfation in different
tissues. Chondroitin sulfate B also belongs to the class of
CSGAGs, and is composed of acetyl galactosamine just
like chondroitin sulfate A and chondroitin sulfate C; the
uronic acid, however, is not only one, and both glucuronic
acid and iduronic acid are present in the polymer. The
class of heparan sulfate/heparin glycosaminoglycans
(HSGAGs) encompasses heparan sulfate and heparin.
All HSGAGs are sulfated and they are composed of acetylglucosamine and of a uronic acid that could be either
glucuronic acid or iduronic acid. The iduronic acid/glu-
curonic acid ratio is higher for heparin in comparison with
heparan sulfate. All glycosaminoglycans are covalently
linked to a protein core as proteoglycans [1]. The glyco-
saminoglycans in tissues and cells can be found either
free, or noncovalently associated with proteins and phos-
pholipids [2]. In human plasma all glycosaminoglycans
can be found [3], and CSGAGs andHSGAGs are themost
abundant [4,5]. Both classes of glycosaminoglycans inter-
act with plasma proteins; HSGAGs, however, show the
tightest association with plasma proteins, and this charac-
teristic renders their extraction and purification from
plasma quite difficult [6,7].
Among plasma glycosaminoglycans, HSGAGs are of
particular interest because they are endowed with
peculiar biological activities. Indeed, HSGAGs, and
heparin in particular, are involved in the control of
hemostasis and also regulate angiogenesis [8]. As far as
the hemostatic balance is concerned, it is believed thatorized reproduction of this article is prohibited.
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antithrombotic activity analogous to that observed with
their pharmacological counterparts (i.e. high-molecular-
weight and low-molecular-weight heparins) [9]. In partic-
ular, since HSGAGs are strongly associated with plasma
proteins, it is not known whether this physiological
association modifies their anticoagulant, antithrombotic
activities.
We recently developed a method to identify and quantify
glycosaminoglycans in human plasma even when they are
still associated with peptides [5], and we have described
the distribution of CSGAGs and HSGAGs in fractions
obtained by fractionating plasma according to themethod
of Cohn–Oncley [10]. In the present study, we evaluated
the anticoagulant activity of the extracts obtained by both
cryoprecipitate and Cohn–Oncley fractions (containing
glycosaminoglycans and peptides, still associated after
proteolysis). The effects on the activities of the coagu-
lation factors II and X of those extracts containing
HSGAGs were also measured, before and after treatment
with heparinase I. The present study clearly demon-
strated that HSGAGs endowed with anticoagulant
activity circulate in normal plasma and that their associ-




Plasma was prepared from samples of 200ml citrated
blood. In this study, three 200ml samples, each obtained
from a different healthy donor, were provided by the
Centre for Blood Transfusion of the Military Pharma-
ceutical Institute (Centro Trasfusionale Militare, Istituto
Farmaceutico Militare) of Firenze, Italy. The donors
were military recruits undergoing standard army physical
training consisting of running (2 km/day), marching
(5 km/day) and free fitness activity. The standard
HSGAGs used in this study were: unfractionated heparin
(UHP) [average molecular weight, 12.9 kDa; sulfation
degree: SO3
/COO, 2.15; activated partial thromboplas-
tin time (APTT), 64 IU/mg], extracted from bovine
intestinal mucosa, and fractions of heparin, termed
low-molecular-weight heparin (LMWHP 2123/850; aver-
age molecular weight, 4.5 kDa; sulfation degree:
SO3
/COO, 2.19; APTT, 37 IU/mg) – both provided by
Opocrin (Modena, Italy). Chondroitin sulfate A, chymo-
trypsin (EC 3.4.21.1), trypsin (EC 3.4.21.4), collagenase
(EC 3.4.24.3), pepsin (EC 3.4.23.1), chondroitinase ABC
(EC 4.2.2.4) and heparinase I (EC 4.2.2.7), were from
Sigma Chemical Co. (St Louis, Missouri, USA). Papain
(EC 3.4.22.2) was from Calbiochem (La Jolla, California,
USA). Titan III Zip Zone cellulose acetate sheets
(60 76mm2) were purchased from Helena Laboratories
(Beaumont, Texas, USA). Alcian Blue was from Fisher
Scientific Co. (Pittsburg, Pennsylvania, USA). Dialysisopyright © Lippincott Williams & Wilkins. Unauthomembranes (cutoff point, 3.5 kDa) were from Spectrum
(Breda, The Netherlands). Azur A was from BDH
(Poole, UK). Polyacrylamide gel electrophoresis (PAGE)
reagents and all common other reagents were from Sigma
Chemical Co. The reagents for evaluation of the APTT
(APTT lyophilized silica for ACL analyzers) were from
Instrumentation Laboratory (Milan, Italy). Factor II-
deficient plasma (0008466050) and factor X-deficient
plasma (0008466350), both from Instrumentation Labora-
tory, were used to evaluate the effects of HSGAGs on
factor II and factor X activities, following the instructions
of the manufacturer using an ACL Advance coagul-
ometer.
Plasma protein fractionation according to the
Cohn–Oncley method
Plasma obtained from each healthy donor was frozen in
a glass beaker at 208C for 24 h. The plasma was then
defrosted at 48C for 24 h, and afterwards it was centri-
fuged at 15 000g for 10min. We obtained a supernatant,
termed cryosupernatant, and a precipitate, termed cryo-
precipitate. We then followed the Cohn–Oncley frac-
tionation procedure as previously described [11].
Glycosaminoglycan extraction from cryoprecipitate and
Cohn-Oncley fractions
Cryoprecipitate and fraction I, fraction IIþIII, fraction
IV-1, fraction IV-4, and fraction V were suspended in
0.05mol/l Tris–HCl, pH 7.4, and were treated with
proteases added sequentially as follows: papain, trypsin,
chimotrypsin, collagenase and pepsin [5]. After proteol-
ysis, the sample was centrifuged at 15 000 g for 10min,
and the supernatant was treated with ethanol to precipi-
tate glycosaminoglycans [5]. The precipitate was resus-
pended in distilled water, dialysed against distilled water,
and lyophilized. The retentate was dissolved in distilled
water and stored at –80 until use.
Quantization of glycosaminoglycans
The retentate extracted from both the cryoprecipitate
and the Cohn–Oncley fractions of human plasma was
analyzed on cellulose acetate electrophoresis at pH 5.0,
following the modification of this procedure that allows
migration of glycosaminoglycans even in the presence of
peptides or proteins [5]. To evaluate HSGAGs in the
fractions, each sample was analyzed on cellulose acetate
electrophoresis after treatment with nitrous acid that
selectively degrades HSGAGs, according to Cappelletti
et al. [12]. The bands were analyzed by densitometry for
quantitative analysis using dedicated software (Scion
Image; Scion Co., Gaithersburg, Maryland, USA), before
and after treatment with nitrous acid. The results con-
cerning quantization of glycosaminoglycans in human
plasma are presented in Table 1 as the meanSD
(n¼ 3 individuals).rized reproduction of this article is prohibited.
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Table 1 Distribution of glycosaminoglycans in Cohn–Oncley







Cryoprecipitate 51493 52.2 47.8
Fraction I 48924 48.4 51.5
Fraction IIþIII 60692 5.9 94.1
Fraction IV-1 48338 30.5 69.0
Fraction IV-4 1748 0.0 100.0
Fraction V 15732 0.0 100.0
Indicated amounts of glycosaminoglycans are referred to 1 ml starting plasma
sample. Data presented as the meanSD of three different electrophoretic runs
for each fraction obtained from the three healthy donors. Cryoprecipitate and
fractions I, IIþIII, IV-1, IV-4 and V, fractions obtained by the Cohn–Oncley
fractionation procedure; CSGAGs, class of chondroitin sulfates; HSGAGs, class
of heparan sulfate and heparin.Measure of the anticoagulant activity
Anticoagulant activity was measured by the APTT-based
one-stage clotting time assay. Normal pooled plasma
was used as the substrate, and the clotting time was
recorded after adding appropriate amounts of each
retentate [13].
Effect on factor II and factor X activity
The retentate from both the cryoprecipitate and Cohn–
Oncley fractions I, IIþIII, and IV-1 (i.e. those containing
HSGAGS) was evaluated for its effect on both factor II
and factor X activity, either before or after treatment with
heparinase I. An aliquot of each retentate was added to
normal control plasma and the tests were performed
following the instructions of the manufacturer (Instru-
mental Laboratories); results are reported as the percen-
tage variation of the factor activity.
Quality controls concerning the APTT and factor II and
factor X activity determinations were carried out on a
daily basis in a Quality Certified Laboratory for Clinical
Analysis (Institute for Clinical Research Manfredo Fan-
fani, Firenze, Italy) before performing the reported deter-
minations. Quality controls were performed according to
the Internal Quality Control System of the Institute and
according to the External Quality Assessment System
provided by the Reference Centre for Safety and Quality
of the Italian Ministry of Health. For each test, the
maximum and confidence limits are provided, and the
expected and calculated mean values are considered.
Enzymatic treatments
Treatment with heparinase I was carried out in order to
selectively degrade HSGAGs. Treatment was performed
adding 10 IU enzyme to 10mg total glycosaminoglycans
of the sample for 24 h at 378C [14].
Treatment with chondroitinase ABC was carried out in
order to selectively degrade CSGAGs. Treatment
was performed by adding 0.1 U enzyme to 10mg total
glycosaminoglycans of the sample for 24 h at 378C [15].opyright © Lippincott Williams & Wilkins. UnauthPolyacrylamide gel electrophoresis analysis
Samples treated with chondroitinase ABC were analyzed
by PAGE, following the method previously described
[16]. After electrophoresis, gels were stained with Azur A
in order to evidence glycosaminoglycans. The molecular
weight of HSGAGs extracted from human plasma was
determined by comparing the migration of standard
HSGAGs of different molecular weight.
Results
Cohn–Oncley fractionation of plasma yields a cryopre-
cipitate and five fractions termed fraction I, fraction
IIþIII, fraction IV-1, fraction IV-4, and fraction V. Each
extracted fraction (the retentate) contains glycosamino-
glycans and peptides still associated after extensive
proteolysis [5].
Table 1 presents the results of the densitometric qual-
itative and quantitative analysis of glycosaminoglycan
bands separated by cellulose acetate electrophoresis of
retentates from both cryoprecipitate and Cohn–Oncley
fractions of the healthy plasma donors used in this study.
In particular, CSGAGs were recovered from both cryo-
precipitate and all Cohn–Oncley fractions, whereas
plasma HSGAGs sensitive to nitrous acid were recovered
only from cryoprecipitate, and fractions I, IIþIII and
IV-1. The results presented in Table 1 refer to the means
obtained from three healthy donors, and it is worth noting
that qualitative and quantitative distribution of glycosa-
minoglycans in these plasma samples paralleled that
previously described [5].
The retentate from both cryoprecipitate and each Cohn–
Oncley fraction was then tested for anticoagulant activity
by the APTT. As a control, the same test was performed
using different amounts of standard HSGAGs: UHP
(average molecular weight, 12.9 kDa; APTT, 164 IU/
mg), and low-molecular-weight heparin (average molecu-
lar weight, 4.5 kDa; APTT, 37 IU/mg) were used as
standard HSGAGs with different anticoagulant activity
(Table 2). The aliquot of each retentate tested for the
APTT was that containing an estimated amount of
HSGAGs of approximately 150 or 900 ng, in order to
compare the effects with those of standard heparin used
(see Table 2). These results demonstrated that only the
retentates from fractions containing HSGAGs (i.e. cryo-
precipitate and fractions I, IIþIII and IV-1), showed
anticoagulant activity. The retentates from fractions con-
taining uniquely CSGAGs (fractions IV-4 and V) did not
show anticoagulant activity. The specific activity of natu-
rally occurring HSGAGs was, however, significantly
lower than that of UHP.We therefore decided tomeasure
the molecular weight of the HSGAGs recovered from the
cryoprecipitate and Cohn–Oncley fractions. Each reten-
tate was treated with chondroitinase ABC, in order to
selectively degrade CSGAGs, and was then analyzed by
PAGE (Fig. 1). HSGAGs in cryoprecipitate and fraction Iorized reproduction of this article is prohibited.
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Table 2 Activated partial thromboplastin time of different amounts of the standard class of heparan sulfate and heparin (HSGAG) and of the
sample obtained from cryoprecipitate and Cohn–Oncley fractions of human plasma
Time (s) Total glycosaminoglycans (ng) HSGAGs (ng)
No addition 30.15 –
Unfractionated heparin 42.90 150 150
Unfractionated heparin 107.90 900 900
Low-molecular-weight heparin 35.30 150 150
Low-molecular-weight heparin 57.00 900 900
Cryoprecipitate 73.70 1676 900
Fraction I 72.70 1872 900
Fraction IIþIII 33.40 2070 150
Fraction IV-1 58.10 1783 900
Fraction IV-4 29.10 1659 0
Fraction V 28.35 1940 0
Results from a typical experiment representative of the three other different plasma fractionations that gave qualitatively identical results. The amounts of glycosami-
noglycans (ng) represent those added to 500ml pooled plasma used for the activated partial thromboplastin time. Unfractionated heparin activated partial thromboplastin
time, 164 IU/mg; low-molecular-weight heparin activated partial thromboplastin time, 37 IU/mg. Cryoprecipitate and fractions I, IIþIII, IV-1, IV-4 and V, sample extracted from
the corresponding fractions obtained by Cohn–Oncley fractionation procedure.showed a high molecular weight (15–18 kDa); that is,
higher than that of UHP (average molecular weight,
12.9 kDa). HSGAGs in fraction IV-1 showed a molecular
weight of about 12.0 kDa, similar to that of UHP. PAGE
could not evidence migration of chondroitinase ABC-
resistant glycosaminoglycans in fraction IIþIII.
We then decided to measure the effects of the retentates
containing HSGAGs and peptides on factor II and factor
X activity, before and after treatment with heparinase I.
The results are shown in Fig. 2. The amount of HSGAGs
from each fraction, incubated for evaluating the effects on
factor II and factor X activity, was the same as that ofopyright © Lippincott Williams & Wilkins. Unautho
Fig. 1
Polyacrylamide gel electrophoresis (PAGE) of heparan sulfates/heparin
(HSGAGs) from Cohn–Oncley fractions of human plasma. Samples
were run on PAGE and then colored with Azur A: HSGAGs showed
evident methachromasia. 1, unfractionated heparin (average molecular
weight, 12.9 kDa) (5mg); 2, chondroitin sulfate A (5mg), digested by
chondroitinase ABC; 3, retentate from cryoprecipitate, digested by
chondroitinase ABC; 4, retentate from fraction I, digested by
chondroitinase ABC; 5, retentate from fraction IIþIII digested by
chondroitinase ABC; 6, retentate from fraction IV-1 digested by
chondroitinase ABC; 7, low-molecular-weight heparin (average
molecular weight, 4.5 kDa) (5mg). This was a typical experiment
representative of three experiments, which gave qualitatively
superimposable results.standardUHP (900 ng) used as a positive control, with the
exception of fraction IIþIII (150 ng HSGAGs tested)
(see legend to Fig. 2). According to the characteristics
of the method, and to the quality control system adopted,
variations less than 2 and 1% (for factor II and factor X
activity, respectively) were considered in the normal
range. Standard UHP showed an inhibitory effect sensi-
tive to heparinase I on factor X activity (Fig. 2b, lane 2),
whereas the inhibitory effect on factor II activity was
close to the limit of the normal range; however, even this
minimal inhibitory effect disappeared after heparinase I
treatment (Fig. 2a, lane 2). The retentate from Cohn’s
fraction I showed an effect similar to that of UHP
(Fig. 2a,b, lanes 4). Cryoprecipitate did not modify factor
II and factor X activities, which remained within the
normal range (Fig. 2a,b, lanes 3). Oddly enough, the
treatment of cryoprecipitate with heparinase I evoked
stimulation of factor II activity (Fig. 2a, lane 3). We
interpret this result as the peptides in cryoprecipitate
stimulating the activity of factor II, and this being inhib-
ited by HSGAGs; heparinase I, removing this inhibition,
restored the stimulatory effect. These two samples (i.e.
retentates from cryoprecipitate and fraction I) were the
most active in prolonging the APTT (i.e. the test measur-
ing both the intrinsic and common pathways of coagu-
lation system), so the results shown in Fig. 2 suggest that
HSGAGs from these fractions are mostly inhibitory on
the intrinsic pathway of coagulation, since evaluation of
factor II and factor X activity were carried out using the
prothrombin time test, which evaluates the extrinsic and
common pathways of coagulation system.
The retentate from fraction IIþIII showed a stimulatory
effect both on factor II and factor X activities (Fig. 2a,b,
lanes 5). Treatment with heparinase I, however, changed
the effect from stimulatory to inhibitory. The retentate
obtained by fraction IV-1 showed a significant inhibitory
effect both on factor II and factor X activity (Fig. 2a,b,
lanes 6). The inhibitory effect on factor X activity was
sensitive to heparinase I treatment in a manner similar torized reproduction of this article is prohibited.


























































Factor II and factor X activity. The activity of (a) factor II and (b) factor X
was measured using a pooled plasma incubated with standard deficient
plasma in the absence of (lane 1) or in the presence of 900 ng standard
unfractionated heparin (lane 2). The effect of the retentate from both
cryoprecipitate and Cohn–Oncley fractions was measured by adding
900 ng heparan sulfates/heparin (HSGAGs) from cryoprecipitate (lane
3), fraction I (lane 4) and fraction IV-1 (lane 6), and 150 ng HSGAGs
from fraction IIþIII (lane 5) to pooled plasma. The effect was measured
before (solid bars) and after (white bars) treatment with heparinase I.
Reported are the results from one experiment representative of three
others, which gave qualitatively identical results.that observed with UHP or with the retentate from
Cohn–Oncley’s fraction I. In other words, treatment with
heparinase I restored factor X activity within the normal
range. As far as factor II activity was concerned, treatment
of the retentate obtained by fraction IV-1 with heparinase
I shifted the effect from inhibitory to stimulatory in
analogy to what observed with cryoprecipitate (Fig. 2a,
lane 3).
Discussion
Glycosaminoglycans play a role in different physiological
and pathological conditions [1,8]. Among plasmatic
glycosaminoglycans, HSGAGs are of particular interest
because of their multifaceted biological activities. More-
over, HSGAGs are known to show different, and in some
cases opposite, biological properties [17]. All plasmatic
glycosaminoglycans circulate in association with a num-
ber of proteins. The association between HSGAGs andopyright © Lippincott Williams & Wilkins. Unauthplasma proteins was the object of several studies, but this
notwithstanding, little is known about the physiological
role of this strong association [3,6]. Indeed, plasmatic
glycosaminoglycans, in particular HSGAGs, are so
strongly associated with proteins that complete purifi-
cation of HSGAGs from healthy individuals is quite a
long and difficult process, unsuitable for routine analysis
of plasmatic HSGAGs [7]. We therefore opted for analyz-
ing plasmatic glycosaminoglycans even in the presence of
peptides remaining after proteolysis [5]. We observed
that CSGAGs were recovered from all Cohn–Oncley
fractions of human plasma and cryoprecipitate, whereas
HSGAGs were recovered only from cryoprecipitate, frac-
tions I and IV-1, and, in a smaller amount, from fraction
IIþIII.
We then decided to evaluate the APTT activity in the
extracts obtained from these fractions. The first report on
the usefulness of the APTT for monitoring anticoagulant
therapy appeared in 1962 [18]; ever since, the APTT has
become the most popular laboratory test for monitoring
full-dose heparin therapy. We observed that the anti-
coagulant activity, assessed as the APTT, paralleled the
distribution of HSGAGs. Plasmatic HSGAGs were
heterogeneous for molecular weight. High-molecular-
weight HSGAGs were associated with cryoprecipitate
and fraction I; that is, those fractions containing proteases
involved in the coagulation cascade [19–21]. Fraction
IV-1, containing antithrombin III [22], showed HSGAGs
of smaller size (12.0 kDa). The presence of high amounts
of peptides in the retentate from fraction IIþIII could
be responsible for the lack of visualization of HSGAGs
by PAGE (Fig. 1). This result appears at odds with the
results reported in Tables 1 and 2, where only a small
amount of HSGAGs endowed with anticoagulant activity
could be detected in fraction IIþIII. Moreover, the
results of PAGE indicated that the low specific activity
of naturally occurring HSGAGs, lower than that of stan-
dard UHP, could not be directly related to their molec-
ular weight.
Worth noting is that the bulk of plasma proteins was
partitioned in fractions IIþIII, and V (i.e. those fractions
containing immunoglobulins and albumin, respectively).
HSGAGs endowed with anticoagulant activity therefore
did not appear randomly associated with plasma proteins.
Most coagulation factors and proteins involved in the
control of hemostasis are concentrated in cryoprecipitate
(fibrinogen, von Willebrand/factor VIII complex) and in
fractions I (factor IX, factor X and prothrombin) and IV-1
(antithrombin III and protein C) [19–23]. These are the
fractions where the highest amount of anticoagulant
HSGAGs was recovered, thus suggesting a specific
association of HSGAGs with proteins involved in hemo-
static balance. We previously demonstrated that these
HSGAGs were not ‘bona fide’ purified because they were
still associated with peptides remaining after proteolysis;orized reproduction of this article is prohibited.
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for HSGAGs [5]. The co-presence of peptides remaining
after proteolysis could be responsible for the low specific
activity as well as for some effect observed on factor II
and factor X activity. In fact, the retentate from fraction
IIþIII, which contains the highest amount of peptides,
showed a stimulating effect on both factor II and factor X
activity (Fig. 2a,b, lanes 5); however, this effect was
sensitive to heparinase I treatment of HSGAGs,
suggesting that interaction between peptides and
HSGAGs of different molecular weight could modulate
their activity. The increase of factor II activity observed
when retentates from both cryoprecipitate and fraction
IV-1 were treated with heparinase I could be also related
to the presence of peptides with stimulating effect on
factor II activity that are inhibited by HSGAGs.
More than 100 proteins have been identified that bind
exogenous HSGAGs, including proteins involved in
hemostasis (inhibitors of coagulation as antithrombin
III, but also coagulation factors), many growth factors,
proteins involved in lipid metabolism and proteins of the
extracellular matrix [24]. Whether these proteins in
plasma interact with endogenous circulating HSGAGs
in vivo, however, is still unknown.
In conclusion, the results described in this paper demon-
strate that different classes of endogenous plasmatic
HSGAGs endowed with anticoagulant activity circulate
in normal human plasma possibly complexed/assembled
with specific proteins that could be separated by Cohn–
Oncley fractionation of plasma. Although the number of
tested participants was limited (n¼ 3), the results con-
cerning the amount of HSGAGs recovered in plasma are
consistent with those reported in the literature [4–7].
The authors also suggest that their binding to specific
plasma proteins (and/or peptides resulting from proteol-
ysis) could play a role in the hemostatic balance. Further
studies are needed, however, to assess complexing of
naturally occurring HSGAGs with plasma proteins.
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